Pharma Stock With Massive Rs 377 Per Share Dividend, Will Go Ex-Dividend On April 28

Sanofi India has declared a robust dividend of Rs 194 per share and Rs 183 per share as final and special dividend. The shares of the company will go ex dividend on April 27 for dividends.

The company has a very consistent track record of paying dividends and is one of the top pharma companies. Sanofi India's Pan-India footprint reaching 2,500 distributors and 1,00,000 pharmacies. 70% of sales stemming from top 7 brands, well-entrenched in stakeholder minds (HCP+patients). The company has been at the forefront of diabetes care, for many decades.

Late last year, Sharekhan had placed a buy on the stock for a price target of Rs 6795. "Sanofi derives a high share of revenues from the chronic focused therapies of diabetology (present in both insulins and orals) and cardiology. In addition to this, it is also present in the areas of thrombosis, epilepsy, allergies, and infections. Its three key products - Lantus, Allegra, and Combiflam have retained leadership in their respective segments and are also amongst the top 100 pharmaceutical brands in India. Sanofi has a wide portfolio of anti-diabetic medicines, with a larger portion of insulins followed by oral solids. In India, Sanofi is among the leading players in the anti-diabetic category," the brokerage had noted.

According to the Sharekhan report, Sanofi India was looking to fortify its presence further, backed by likely faster growth in key brands such as Lantus. "Also in July 2021, the company launched Toujeo in a unique Toustar pen. The concept of the dedicated pen is pioneered by Sanofi. In addition to the insulins, orals - which include brands like Amaryl and Amaryl MV too have been amongst the leading in their respective categories. Both cardiology and anti-diabetes segments have been among the consistently growing therapy areas in IPM and as the demand outlook stays strong. Going ahead, expected traction in key brands - Allegra, Lantus, and Combiflam coupled with new launches is expected to support the growth of Sanofi," the company stated in its report.